Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:47:36.057Z.
Calculation as of: 2026-10-06T20:47:36.057Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
PE RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.07M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.91M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.07M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 14.43 | 22.48 | 68.28 | 68.28 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A | 26.24 | 26.24 | 26.24 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A | 8.07 | 11.31 | 11.31 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.91 | 6.53 | 42.60 | 42.60 |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
